Industry Trends

Round discusses how he adjusted his leadership style and approach to patient care in the most effective way during the pandemic.

DiMambro discusses how companies can update their systems and strategies to collect data which ensures that marginalized groups and diverse voices are included.

Ford discusses how rising drug costs in impact patients, and how they can either avoid them or find less-expensive options.

Larger pipeline and increased support from regulatory authorities are setting up the orphan drug market for long-term success.

Industry must continue research and development to combat the pandemic.

Flesch speaks with Pharm Exec about his work to bring a patient-centric approach to the forefront of the industry.

Investments setting up sector for future success that could one day rival its US counterpart.

COVID-19 pandemic has accelerated raised expectations for medical information professionals.

Moorman discusses critical aspects of key account management in pharma.

While patients continue to benefit from increased product launches, the pandemic is still having an impact on caseload.

Szwarcberg discusses challenges in the rare disease drug development space, and how his background is helping him find solutions for patients, specifically with endocrine disorders.

Recent explosion at Zaporizhzhia nuclear power plant in Ukraine shows how pharma industry can pull together and take action in the face of adversity.

Pandemic workforce trends continue to create challenges for pharma.

Improvements in R&D, manufacturing, and data sharing will extend platform’s reach.

Upcoming regulatory changes to create new opportunity for specialized offerings.

Industry has shown it can overcome challenges en route to creating new therapies.

Rise in demand for sustainable practices forces industry to be more proactive.

Hill shares her insights on what is needed for a turnaround in talent development.

New mediums of technology must be utilized correctly to reap full benefits.

New regulations set stage for updated ESG considerations.

New C-Suite position emerges for more emphasis on patient centricity.

From exposing disparities in care to guiding better patient outcomes to helping reign in the costs of care, the use of real-world data (RWD) in oncology can have far-reaching effects. Here’s how one RWD company exec is using her experience to help drive that change.

Why purpose-driven firms are now more important than ever.

Cross-sector businesses are banding together to protect their intellectual property, but there’s a better way to do it.

Rush shares his thoughts on how advanced analytics are making their mark on the pharma industry.

Brennan describes what her career journey in pharma has looked like as a woman, and what she feels can be done to improve opportunities for other females in pharma. She also talks about how advocacy and commitment can similarly be applied to improve the rare disease space.

Mary Jo Struttmann, executive director of alliance management for Astellas discusses how to form strategic partnerships to bring new drugs to market and how to navigate partnerships, alliance dynamics, and potential challenges in 2022 and beyond.

Study analyzes mainstream media coverage of the industry before and after the COVID-19 lockdown.

Full-year business review of pharma and biotech sectors reveals strong momentum in advancing novel science and treatments, but likely foretells continued stock instability in near-to-medium terms.

A look at the renewed efforts of biopharma companies in exploring age-old substances to treat mental health conditions and more, minus the negative effects.